Literature DB >> 9674800

Angiographically defined primary angiitis of the CNS: is it really benign?

A R Woolfenden1, D C Tong, M P Marks, A O Ali, G W Albers.   

Abstract

BACKGROUND: Primary angiitis of the CNS (PACNS) is a diagnostically challenging disorder. In patients whose diagnosis is ascertained solely by cerebral angiography without histologic verification, a benign monophasic clinical course with favorable response to a brief course of immunosuppressive therapy is often reported.
METHODS: We performed a retrospective review of patients with PACNS seen at the Stanford Stroke Center.
RESULTS: Patients were followed for a median of 27.5 months. Acute focal deficits (9 of 10) and headache (3 of 10) were the most frequent presenting symptoms. Significant recurrent neurologic symptoms occurred in 5 of 10 patients before the initiation of immunosuppressive treatment. Three of six patients had recurrent symptoms during prednisone therapy alone, whereas only one of seven patients had recurrent symptoms while receiving combination immunosuppressive therapy. None had recurrent stroke during immunosuppressive treatment. Dynamic arterial changes were seen in four of five patients who underwent follow-up angiography that often, but not always, correlated with disease activity.
CONCLUSIONS: Patients with angiographically defined PACNS frequently did not have a benign outcome or monophasic course. Repeat angiography was useful in supporting the diagnosis of PACNS, but did not always correlate with disease activity. A prospective multicenter collaborative effort is required to better define the clinical course and optimal treatment of PACNS.

Entities:  

Mesh:

Year:  1998        PMID: 9674800     DOI: 10.1212/wnl.51.1.183

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  Reversible cerebral vasoconstriction syndromes.

Authors:  Richard A Bernstein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

2.  MR imaging and angiography of primary CNS vasculitis of childhood.

Authors:  R I Aviv; S M Benseler; E D Silverman; P N Tyrrell; G Deveber; L M Tsang; D Armstrong
Journal:  AJNR Am J Neuroradiol       Date:  2006-01       Impact factor: 3.825

3.  Non-atherosclerotic vascular disease in the young.

Authors:  Osvaldo Camilo; Larry B Goldstein
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

Review 4.  Vasculitis of the central nervous system.

Authors:  P M Moore
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 5.  The Role of Catheter Angiography in the Diagnosis of Central Nervous System Vasculitis.

Authors:  Randall C Edgell; Ahmed E Sarhan; Jazba Soomro; Collin Einertson; Joanna Kemp; Peyman Shirani; Theodore K Malmstrom; Jeroen Coppens
Journal:  Interv Neurol       Date:  2016-08-11

Review 6.  Central nervous system vasculitis.

Authors:  Sterling G West
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

7.  An update of the Mayo Clinic cohort of patients with adult primary central nervous system vasculitis: description of 163 patients.

Authors:  Carlo Salvarani; Robert D Brown; Teresa Christianson; Dylan V Miller; Caterina Giannini; John Huston; Gene G Hunder
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

Review 8.  Diagnostic test results in primary CNS vasculitis: A systematic review of published cases.

Authors:  Ferghal McVerry; Gavin McCluskey; Peter McCarron; Keith W Muir; Mark O McCarron
Journal:  Neurol Clin Pract       Date:  2017-06

Review 9.  Primary angiitis of the central nervous system: diagnosis and treatment.

Authors:  Carolin Beuker; Antje Schmidt; Daniel Strunk; Peter B Sporns; Heinz Wiendl; Sven G Meuth; Jens Minnerup
Journal:  Ther Adv Neurol Disord       Date:  2018-07-09       Impact factor: 6.570

Review 10.  [Clinical aspects and diagnostics of cerebral vasculitis].

Authors:  W Reith; C Kraus; N Harsch
Journal:  Radiologe       Date:  2016-10       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.